Treg Vaccination in Autoimmune Type 1 Diabetes
Treg Vaccination in Autoimmune Type 1 Diabetes
复制标题
DOI：
10.1007/s40259-013-0060-3
复制
发表时间：
2014-02
期刊：
影响因子：
6.8
通讯作者：
Isabelle Serr;B. Weigmann;R. K. Franke;C. Daniel
中科院分区：
文献类型：
--
作者：
Isabelle Serr;B. Weigmann;R. K. Franke;C. Daniel
Foxp3+调节性T（Treg）细胞是建立和维持免疫自身耐受的关键贡献者。自身免疫性1型糖尿病（T1D）的特征是对胰腺中产生胰岛素的β细胞的自身耐受性丧失和β细胞的破坏，导致诊断时发生慢性高血糖症。在亚免疫原性条件下提供的强激动性T细胞受体配体的应用作为幼稚CD4+T细胞有效从头转化为Foxp3+Treg细胞的关键手段。因此，在供应某些自身抗原的强激动性变体时Treg细胞的特异性诱导可以作为关键工具发挥作用，以便通过恢复自身耐受性来实现自身免疫性如T1D的安全和特异性预防。正在开发这种免疫策略，并且在T1D的情况下，旨在限制自身免疫和β细胞破坏。在这篇综述中，我们讨论了以干扰自身免疫性T1D为目标的基于Treg的耐受方法的要求和机会。
Foxp3+regulatory T (Treg) cells are critical contributors to the establishment and maintenance of immunological self-tolerance. Autoimmune type 1 diabetes (T1D) is characterized by the loss of self-tolerance to the insulin-producing β cells in the pancreas and the destruction of β cells, resulting in the development of chronic hyperglycemia at diagnosis. The application of strong-agonistic T-cell receptor ligands provided under subimmunogenic conditions functions as a critical means for the efficient de novo conversion of naive CD4+T cells into Foxp3+Treg cells. The specific induction of Treg cells upon supply of strong-agonistic variants of certain self-antigens could therefore function as a critical instrument in order to achieve safe and specific prevention of autoimmunity such as T1D via the restoration of self-tolerance. Such immunotherapeutic strategies are being developed, and in the case of T1D aim to restrict autoimmunity and β-cell destruction. In this review, we discuss the requirements and opportunities for Treg-based tolerance approaches with the goal of interfering with autoimmune T1D.